ArticleCancer research communications2026
A Multicenter Retrospective Outcomes Analysis of Patients with Localized Synovial Sarcoma.
Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
To identify clinicopathologic factors associated with outcomes in patients with localized synovial sarcoma (SS). We retrospectively reviewed 248 patients with localized SS treated across three US quaternary medical centers between 2000 and 2024. Demographics, tumor characteristics, and treatments, including perioperative chemotherapy and radiotherapy (RT), were assessed. Disease-free survival (DFS) and overall survival (OS) were estimated via Kaplan-Meier analysis, and Cox regression was used for univariable and multivariable analysis, including significant univariate factors and confounders such as age and tumor size. Median follow-up was 5.2 years; median age at diagnosis was 35 years (IQR, 26-46). Median DFS was 110.3 months. Perioperative chemotherapy was given to 150 (60%) patients, whereas perioperative RT was given to 173 (69.8%) patients. Multivariable analysis showed that tumor size correlated with worse DFS (P < 0.001) and OS (P < 0.001), whereas a location in the chest wall, trunk, or extremities correlated with improved DFS (P = 0.006). Percent tumor necrosis was associated with worse OS (P = 0.04), whereas R0 (P = 0.002) resection margins correlated with improved OS. Perioperative RT or chemotherapy did not correlate with OS or DFS in the whole cohort, though patients with tumor size ≥10 cm (n = 47) showed worse OS when receiving perioperative chemotherapy only as opposed to combined perioperative chemotherapy and RT (P = 0.006). Tumor size, location, margin status, and tumor necrosis are independent prognostic factors in localized SS. Combined perioperative chemotherapy and RT correlated with improved OS in patients with tumors larger than 10 cm. SIGNIFICANCE: SS is a rare, aggressive malignancy with limited perioperative data. In this multi-institutional study of 248 patients with localized disease, tumor size, location, and margin status predicted recurrence and survival. Combined perioperative chemotherapy and RT benefited patients with larger tumors but not across the overall cohort, supporting risk-adapted management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.